Here's Why Everybody's Talking About Aurinia Pharmaceuticals Stock

Cory Renauer, The Motley Fool
·4-min read
Here's Why Everybody's Talking About Aurinia Pharmaceuticals Stock

The Food and Drug Administration recently made voclosporin (brand name Lupkynis) the company's first commercial-stage product. Analysts who follow Aurinia Pharmaceuticals have raised their sales estimates for Lupkynis following its approval. Lupkynis is an improvement on cyclosporine, a decades-old immunosuppressive drug used to reduce the risk of post-transplant organ rejection, and the active ingredient in a popular dry eye treatment called Restasis.